Comment from Otsuka Pharmaceutical Development & Commercialization, Inc.

Summary: Otsuka Pharmaceutical Development & Commercialization, Inc. expresses appreciation for the FDA's efforts in creating guidance for protocol deviations in clinical investigations. They provide a specific technical suggestion to clarify reporting requirements for the Study Data Tabulation Model.